Literature DB >> 23712364

[Evidence-based treatment options for allergic diseases in otolaryngology: an update].

L Klimek1, A Sperl.   

Abstract

Allergic diseases in the area of otolaryngology (ENT) are common, increasing and associated with a number of comorbid disorders, such as bronchial asthma and atopic dermatitis. If allergen avoidance is not possible, allergen-specific immunotherapy is the only causative treatment option. Options for pharmacotherapy are mast cell stabilizers, antihistamines, glucocorticoids, leukotriene receptor antagonists and nasal decongestants. In type 1 allergic reactions, topical glucocorticoids are currently the most effective treatment and are considered to be the first-line therapy together with nonsedating antihistamines. A novel formulation (MP29-02) combining a nasal glucocorticoid and antihistamine in one single preparation has demonstrated an improvement of the effective total nasal symptom score by 39 % in comparison to monotherapy with fluticasone propionate. In type IV allergies, such as eczema treatment with topical glucocorticoids or calcineurin inhibitors is standard.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23712364     DOI: 10.1007/s00106-013-2709-0

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  43 in total

Review 1.  The role of antileukotriene therapy in seasonal allergic rhinitis: a systematic review of randomized trials.

Authors:  Gustavo J Rodrigo; Anahi Yañez
Journal:  Ann Allergy Asthma Immunol       Date:  2006-06       Impact factor: 6.347

2.  [Mechanism of action of nasal glucocorticosteroids in the treatment of allergic rhinitis. Part 1: Pathophysiology, molecular basis].

Authors:  L Klimek; P Högger; O Pfaar
Journal:  HNO       Date:  2012-07       Impact factor: 1.284

Review 3.  Bilastine for the relief of allergy symptoms.

Authors:  B Sádaba Díaz de Rada; J R Azanza Perea; A Gomez-Guiu Hormigos
Journal:  Drugs Today (Barc)       Date:  2011-04       Impact factor: 2.245

4.  The effects of an H3 receptor antagonist (PF-03654746) with fexofenadine on reducing allergic rhinitis symptoms.

Authors:  Jeffrey R Stokes; Francisco A Romero; Richard J Allan; Peter G Phillips; Frances Hackman; Janie Misfeldt; Thomas B Casale
Journal:  J Allergy Clin Immunol       Date:  2011-12-22       Impact factor: 10.793

5.  The leukotriene antagonist montelukast as a therapeutic agent for atopic dermatitis.

Authors:  D J Yanase; K David-Bajar
Journal:  J Am Acad Dermatol       Date:  2001-01       Impact factor: 11.527

Review 6.  Rupatadine in allergic rhinitis and chronic urticaria.

Authors:  J Mullol; J Bousquet; C Bachert; W G Canonica; A Gimenez-Arnau; M L Kowalski; E Martí-Guadaño; M Maurer; C Picado; G Scadding; P Van Cauwenberge
Journal:  Allergy       Date:  2008-04       Impact factor: 13.146

7.  Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma.

Authors:  M V Kopp; E Hamelmann; S Zielen; W Kamin; K-C Bergmann; C Sieder; S Stenglein; S Seyfried; U Wahn
Journal:  Clin Exp Allergy       Date:  2008-10-30       Impact factor: 5.018

8.  Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.

Authors:  R Niven; K F Chung; Z Panahloo; M Blogg; G Ayre
Journal:  Respir Med       Date:  2008-07-26       Impact factor: 3.415

9.  Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation.

Authors:  B Samuelsson
Journal:  Science       Date:  1983-05-06       Impact factor: 47.728

10.  Combination therapy with azelastine hydrochloride nasal spray and fluticasone propionate nasal spray in the treatment of patients with seasonal allergic rhinitis.

Authors:  Paul H Ratner; Frank Hampel; Julius Van Bavel; N J Amar; Pramila Daftary; William Wheeler; Harry Sacks
Journal:  Ann Allergy Asthma Immunol       Date:  2008-01       Impact factor: 6.347

View more
  1 in total

1.  [Immunotherapy of allergic rhinitis without allergens? : new options for immunomodulation by vaccination with virus-like particles and CpG motifs].

Authors:  L Klimek; J Willers; P Schendzielorz; T M Kündig; G Senti
Journal:  HNO       Date:  2013-10       Impact factor: 1.284

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.